Radiotherapy for Non-Hodgkin’s lymphoma with cardiac infiltration: A case report

BACKGROUND: Non-Hodgkin’s lymphoma (NHL) with cardiac infiltration has a poor prognosis. The median OS of patients failing to respond to chemotherapy has been reported to be 1 month vs. 18 months in patients responding to chemotherapy. CASE PRESENTATION: Herein, we reported a case of a 57-year-old m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Weifeng, Zhang, Zhuo, Deng, Xiaocong, Gu, Anqi, Chen, Xianzhao, Cai, Yizheng, Zhao, Yuting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616872/
https://www.ncbi.nlm.nih.gov/pubmed/37916159
http://dx.doi.org/10.3389/fonc.2023.1234831
Descripción
Sumario:BACKGROUND: Non-Hodgkin’s lymphoma (NHL) with cardiac infiltration has a poor prognosis. The median OS of patients failing to respond to chemotherapy has been reported to be 1 month vs. 18 months in patients responding to chemotherapy. CASE PRESENTATION: Herein, we reported a case of a 57-year-old male confirmed with diffuse large B-cell lymphoma who received radiation therapy of 150-cGy daily, administered in 30 fractions to the volume of cardiac infiltration, resulting in complete relief. Chemotherapy had no curative effect. The patient was subsequently enrolled in a clinical trial and received oral administration of zanubrutinib 80mg twice daily, after which he achieved complete remission. The progression-free survival was from diagnosis (January 7, 2020) to the follow-up (September 20, 2022), amounting to 32 months. CONCLUSION: Proper irradiation dose and timing of treatment can relieve NHL symptoms.

Ejemplares similares